Modelling disease and cell behaviour using organoids
Problema a solucionar
Many years of successful oncological research are leading to increasing cohorts of cancer survivors. Patients treated with radiotherapy in the abdominal cavity suffer bleeding and ulceration of the intestinal mucosa and in some cases the severity of the pathology may lead to the interruption of cancer treatments. There are no available treatments, consequently there is a need of a fast and cost-effective drug screening platform to identify drugs that boost intestinal regeneration.
Oportunitats de mercat
During the last five years, up to 43.8 million cancer survivors were diagnosed. In addition, 90% of patients treated with abdominal radiotherapy develop enteritis. Currently, there are no available treatments for radiation-induced enteritis. In this context, the quality of life of cancer patients and survivors is a rising concern.
Tecnologia
We postulate that patients suffering radiation-induced enteritis would benefit from therapies that enhance intestinal regeneration. Thus, improving their quality of life. For this we have generated a semi-automated imaging-based intestinal organoids drug screening platform to identify compounds that enhance intestinal regeneration.
Autors
Jordi Guiu
Technology Readiness Level
TRL3
Què busquem?
Potential clients interested in developing a specific organoid model or in drug validation in organoids.